AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has AusCann Group Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AC8 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AC8 underperformed the Australian Pharmaceuticals industry which returned -28.5% over the past year.
Return vs Market: AC8 underperformed the Australian Market which returned -6.9% over the past year.
Price Volatility Vs. Market
How volatile is AusCann Group Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWe're Not Very Worried About AusCann Group Holdings' (ASX:AC8) Cash Burn Rate
5 months ago | Simply Wall StDid You Manage To Avoid AusCann Group Holdings' (ASX:AC8) Devastating 74% Share Price Drop?
6 months ago | Simply Wall StCould AusCann Group Holdings Ltd's (ASX:AC8) Investor Composition Influence The Stock Price?
Is AusCann Group Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AC8's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AC8's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AC8 is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: AC8 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AC8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AC8 is good value based on its PB Ratio (1.3x) compared to the AU Pharmaceuticals industry average (3.2x).
How is AusCann Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AusCann Group Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine AusCann Group Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- AusCann Group Holdings competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has AusCann Group Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AC8 is currently unprofitable.
Growing Profit Margin: AC8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AC8 is unprofitable, and losses have increased over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare AC8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AC8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: AC8 has a negative Return on Equity (-20.43%), as it is currently unprofitable.
How is AusCann Group Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: AC8's short term assets (A$23.6M) exceed its short term liabilities (A$774.8K).
Long Term Liabilities: AC8's short term assets (A$23.6M) exceed its long term liabilities (A$54.4K).
Debt to Equity History and Analysis
Debt Level: AC8 is debt free.
Reducing Debt: AC8 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AC8 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AC8 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.4% each year
What is AusCann Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AC8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AC8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AC8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AC8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AC8's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nick Woolf (52 yo)
Mr. Nicholas Woolf, also known as Nick, MA (OXOM), FCCA has been Chief Executive Officer of AusCann Group Holdings Ltd since August 5, 2020. Mr. Woolf served as Chief Business Officer of Suda Pharmaceutica ...
|Chief Executive Officer||0.17yr||no data||no data|
|CFO & Joint Company Secretary||no data||no data||no data|
|Chief Operating Officer||no data||no data||no data|
|Chief Medical Advisor||0.58yr||no data||no data|
|Joint Company Secretary||4yrs||no data||no data|
Experienced Management: AC8's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
|Independent Non-Executive Director||3.75yrs||AU$65.70k||0.036% |
|Independent Non-Executive Director||0.83yr||AU$31.94k||no data|
|Independent Non-Executive Chairman||0.75yr||AU$43.88k||0.16% |
|Independent Non-Executive Director||0.83yr||AU$29.14k||0.043% |
Experienced Board: AC8's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AusCann Group Holdings Ltd's company bio, employee growth, exchange listings and data sources
- Name: AusCann Group Holdings Ltd
- Ticker: AC8
- Exchange: ASX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$44.387m
- Shares outstanding: 317.05m
- Website: https://auscann.com.au
- AusCann Group Holdings Ltd
- 35 Havelock Street
- Level 5
- West Perth
- Western Australia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AC8||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jan 2017|
|AC8||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jan 2017|
|UVP||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 2017|
|ACNN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 2017|
AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell ca ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 10:31|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.